Q2 2025 Management View Eric M. Dube, President and CEO, described Q2 2025 as "a standout for Travere, a reflection of strong ...

Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the ...

Q2 2025 Earnings Call Transcript August 6, 2025 Travere Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Analysts are estimating that Travere Therapeutics will report an earnings per share (EPS) of $-0.12. The announcement from ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Wednesday reported a loss of $12.8 million in its second quarter. The San Diego-based company said it had a loss of 14 cents per ...

Travere Therapeutics stock suffered a bit of a setback last week as the FDA moved back the anticipated decision date on a recently submitted sNDA. Learn more on TVTX stock here.

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate ...

--Travere Therapeutics, Inc., today announced that the U.S. Food and Drug Administration has granted full approval to FILSPARI ® to slow kidney function decline in adults with primary IgAN who ...

SAN DIEGO — Travere Therapeutics, a biotech focused on treating rare diseases, on Monday announced that a Phase 3 trial of an experimental treatment for focal segmental glomerulosclerosis, a ...

News provided by Travere Therapeutics, Inc. Aug 22, 2022, 7:00 AM ET A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be ...